Schrodinger
Computational drug designing for pharmaceutical and biotechnology research.
Launch date
Employees
Market cap
€1.4b
Enterprise valuation
€1.1b (Public information from Sep 2024)
Share price
$20.84 SDGR
New York City New York (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 108m | 138m | 181m | 217m | 210m | 261m | 302m |
% growth | 26 % | 28 % | 31 % | 20 % | (3 %) | 24 % | 16 % |
EBITDA | (85.5m) | (120m) | (124m) | (225m) | (197m) | (175m) | (154m) |
% EBITDA margin | (79 %) | (87 %) | (69 %) | (104 %) | (94 %) | (67 %) | (51 %) |
Profit | (24.5m) | (100m) | (149m) | 40.7m | (174m) | (176m) | (164m) |
% profit margin | (23 %) | (73 %) | (82 %) | 19 % | (83 %) | (68 %) | (54 %) |
EV / revenue | 45.0x | 13.7x | 4.9x | 11.9x | 4.8x | 4.0x | 3.6x |
EV / EBITDA | -56.8x | -15.8x | -7.1x | -11.4x | -5.2x | -5.9x | -7.2x |
R&D budget | 64.7m | 90.9m | 126m | 182m | - | - | - |
R&D % of revenue | 60 % | 66 % | 70 % | 84 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $31.0m | Series A | |
$10.0m | Late VC | ||
$20.0m | Growth Equity VC | ||
$22.0m | Growth Equity VC | ||
N/A | $80.0m | Late VC | |
* | $85.0m | Series E | |
$110m | Series F | ||
* | N/A | $232m | IPO |
* | N/A | $347m | Post IPO Equity |
* | $4.9m | Grant | |
* | $10.0m | Grant | |
Total Funding | €339m |
Related Content
Recent News about Schrodinger
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Schrodinger
EditACQUISITION by Eli Lilly Jul 2024
ACQUISITION by Schrodinger Jan 2022